<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328143</url>
  </required_header>
  <id_info>
    <org_study_id>17.101</org_study_id>
    <nct_id>NCT03328143</nct_id>
  </id_info>
  <brief_title>Feasibility of Aromatherapy in an Awake Craniotomy Environment</brief_title>
  <official_title>Feasibility of Aromatherapy in an Awake Craniotomy Environment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Awake craniotomy for tumor surgery allows for mapping of speech, motor and sensory function
      during tumor resection. Awake craniotomy is increasingly utilized as it has several
      advantages over a traditional general anesthetic technique. Though many patients tolerate
      awake cranial surgery well, recent studies found that roughly 30% of patients experience
      moderate to severe pain and anxiety, while 50% report moderate fear and 11% report severe
      fear. Therefore, alternative methods to mitigate pain, anxiety, and fear are needed. In this
      study, the investigators will employ lavender aromatherapy to reduce anxiety and improve the
      satisfaction with pain control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 7, 2018</start_date>
  <completion_date type="Anticipated">February 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of consented patients</measure>
    <time_frame>8 hours</time_frame>
    <description>Determine the number of eligible patients enrolled and consented</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol completion</measure>
    <time_frame>8 hours</time_frame>
    <description>Determine the number of consented patients completing the trial protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of Visual Analogue Scale for Anxiety (VAS-A)</measure>
    <time_frame>8 hours</time_frame>
    <description>Measure of anxiety, Total Score (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of Visual Analogue Scale for Pain (VAS-P)</measure>
    <time_frame>8 hours</time_frame>
    <description>Measure of pain, Total Score (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Opinion of Pain Management (POPM) survey</measure>
    <time_frame>8 hours</time_frame>
    <description>Satisfaction with pain control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic and anxiolytic dosage</measure>
    <time_frame>8 hours</time_frame>
    <description>Cumulative dose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intracranial Pathology</condition>
  <arm_group>
    <arm_group_label>Treatment with Lavender</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lavender (Lavandula angustifolia)</intervention_name>
    <description>Lavender (Lavandula angustifolia) is an essential oil.</description>
    <arm_group_label>Treatment with Lavender</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult patient aged 18 and older undergoing awake cranial neurosurgery

        Exclusion Criteria:

          -  Allergy or sensitivity to the aromatherapy agent (Lavender)

          -  Aversion to lavender scent

          -  History of asthma, COPD

          -  History of contact dermatitis following exposure to cosmetic fragrances

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Rovin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Dennison, CIP</last_name>
    <phone>414-385-1913</phone>
    <email>gary.dennison@aurora.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Tutino, RN,MS,CCRC</last_name>
    <phone>414-649-5526</phone>
    <email>carol.tutino@aurora.org</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Craniotomy, anxiety, malignant, cancer, brain tumor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

